{"id":4831,"date":"2025-12-17T13:37:49","date_gmt":"2025-12-17T05:37:49","guid":{"rendered":"https:\/\/credevo.com\/s\/?page_id=4831"},"modified":"2026-01-05T19:12:02","modified_gmt":"2026-01-05T11:12:02","slug":"tofacitinib-citrate-bioequivalence-study-protocol","status":"publish","type":"page","link":"https:\/\/credevo.com\/s\/tofacitinib-citrate-bioequivalence-study-protocol\/","title":{"rendered":"Tofacitinib Citrate Bioequivalence Study Protocol"},"content":{"rendered":"\n
\n

Tofacitinib Citrate (Xeljanz) generates over $2 billion<\/strong> annually as a first-in-class oral JAK inhibitor within the $49.6 billion<\/strong> rheumatology therapeutics market. Patents expire between 2025-2027 across major markets, creating significant opportunities for generic entry. Our optimized bioequivalence protocol, designed for tofacitinib’s exceptionally BE-friendly development profile and minimal variability, supports a 6-8 week<\/strong> development advantage for efficient market entry, enabling early entrants to capture 70-80% <\/strong>of initial volume in a market projected to reach $38.7 billion by 2028<\/strong>.<\/p>\n<\/blockquote>\n\n\n\n

<\/div>\n\n\n\n
\"Xeljanz<\/figure>
\n

Overview<\/strong>: Tofacitinib Citrate (Xeljanz) is used for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis with convenient once or twice daily dosing, offering potent immunomodulation for patients who have failed prior therapies. It is an oral JAK inhibitor that selectively blocks JAK1 and JAK3 to disrupt cytokine signaling pathways involved in immune-mediated inflammation. A bioequivalence study confirms that generic formulations are equivalent to the reference product in terms of systemic exposure and pharmacokinetic profile.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n

Download the complete, submission-ready BE protocol with all technical details<\/p>\n\n\n\n

What This Protocol Includes<\/p>\n\n\n\n

\n
\n
    \n
  • Study Synopsis<\/li>\n\n\n\n
  • Study Design Narrative<\/li>\n\n\n\n
  • PK Parameter Definitions (AUC, Cmax<\/sub>, Tmax<\/sub>, t\u00bd)<\/li>\n\n\n\n
  • Safety and AE\/ SAE Reporting<\/li>\n\n\n\n
  • Sampling Time Points<\/li>\n\n\n\n
  • Schedule of Assessments<\/li>\n<\/ul>\n<\/div>\n\n\n\n
    \n
      \n
    • Washout period<\/li>\n\n\n\n
    • Scientific Rationale & Regulatory Justification<\/li>\n\n\n\n
    • Dosing & Administration<\/li>\n\n\n\n
    • Inclusion\/ Exclusion Criteria<\/li>\n\n\n\n
    • Sample Handling <\/li>\n\n\n\n
    • Statistical Considerations<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n